VVX
V2X, Inc.
Aerospace & Defense
Market Cap$2.84B
5Y Perf.+84.8%
Build Your Comparison
Side-by-side financial analysisVVX
DLB
Try popular comparisons:
Stock Comparison
VVX vs DLB
Revenue, margins, valuation, and 5-year total return — side by side.
DLB
Dolby Laboratories, Inc.
Information Technology Services
Market Cap$5.02B
5Y Perf.-20.3%
VVX vs DLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  VVX |  DLB |
|---|---|---|
| Industry | Aerospace & Defense | Information Technology Services |
| Market Cap | $2.84B | $5.02B |
| Revenue (TTM) | $4.72B | $1.34B |
| Net Income (TTM) | $89M | $241M |
| Gross Margin | 8.5% | 87.9% |
| Operating Margin | 4.3% | 18.8% |
| Forward P/E | 14.9x | 12.2x |
| Total Debt | $1.17B | $39M |
| Cash & Equiv. | $369M | $702M |
VVX vs DLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VVX
DLB
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| V2X, Inc. (VVX) | 100 | 184.8 | +84.8% |
| Dolby Laboratories,… (DLB) | 100 | 79.7 | -20.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VVX vs DLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DLB leads in 6 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. V2X, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇DLB emerged as the overall leader. Track its performance:
VVX
V2X, Inc.
The Growth Play
VVX is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 3.7%, EPS growth 126.9%, 3Y rev CAGR 15.7%
- 251.6% 10Y total return vs DLB's 32.2%
- +100.7% vs DLB's -28.3%
Best for: growth exposure and long-term compounding
DLB
Dolby Laboratories, Inc.
The Income Pick
DLB carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 12 yrs, beta 0.79, yield 2.5%
- Lower volatility, beta 0.79, Low D/E 1.5%, current ratio 3.17x
- Beta 0.79, yield 2.5%, current ratio 3.17x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  DLB | 5.9% revenue growth vs VVX's 3.7% |
| Value | DLB | Lower P/E (12.2x vs 14.9x) |
| Quality / Margins | DLB | 18.0% margin vs VVX's 1.9% |
| Stability / Safety | DLB | Beta 0.79 vs VVX's 0.85, lower leverage |
| Dividends | DLB | 2.5% yield; 12-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) |  VVX | +100.7% vs DLB's -28.3% |
| Efficiency (ROA) | DLB | 7.5% ROA vs VVX's 2.7%, ROIC 10.1% vs 7.7% |
VVX vs DLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
VVX vs DLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDLBLAGGINGVVX
VVXV2X, Inc.
1leads
DLBDolby Laboratories, I…
3leads
6 Total Categories
CATEGORYLEADERvs VVXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DLB4/6
Valuation MetricsMultiples, price ratios, and targets
DLB4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DLB8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
VVX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DLB leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VVX is the larger business by revenue, generating $4.7B annually — 3.5x DLB's $1.3B. DLB is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to VVX's 1.9%. On growth, VVX holds the edge at +23.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| RevenueTrailing 12 months | $4.7B | $1.3B |
| EBITDAEarnings before interest/tax | $289M | $352M |
| Net IncomeAfter-tax profit | $89M | $241M |
| Free Cash FlowCash after capex | $136M | $380M |
| Gross MarginGross profit ÷ Revenue | +8.5% | +87.9% |
| Operating MarginEBIT ÷ Revenue | +4.3% | +18.8% |
| Net MarginNet income ÷ Revenue | +1.9% | +18.0% |
| FCF MarginFCF ÷ Revenue | +2.9% | +28.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +23.4% | -2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +140.0% | -21.4% |
DLB leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
DLB leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 20.0x trailing earnings, DLB trades at a 46% valuation discount to VVX's 37.1x P/E. On an enterprise value basis, VVX's 11.9x EV/EBITDA is more attractive than DLB's 12.0x.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| Market CapShares × price | $2.8B | $5.0B |
| Enterprise ValueMkt cap + debt − cash | $3.6B | $4.4B |
| Trailing P/EPrice ÷ TTM EPS | 37.07x | 20.05x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.91x | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.48x |
| EV / EBITDAEnterprise value multiple | 11.88x | 11.98x |
| Price / SalesMarket cap ÷ Revenue | 0.63x | 3.72x |
| Price / BookPrice ÷ Book value/share | 2.66x | 1.95x |
| Price / FCFMarket cap ÷ FCF | 16.72x | 11.66x |
DLB leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
DLB leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
DLB delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $8 for VVX. DLB carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to VVX's 1.08x. On the Piotroski fundamental quality scale (0–9), VVX scores 8/9 vs DLB's 6/9, reflecting strong financial health.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| ROE (TTM)Return on equity | +8.2% | +9.2% |
| ROA (TTM)Return on assets | +2.7% | +7.5% |
| ROICReturn on invested capital | +7.7% | +10.1% |
| ROCEReturn on capital employed | +8.4% | +9.6% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 6 |
| Debt / EquityFinancial leverage | 1.08x | 0.01x |
| Net DebtTotal debt minus cash | $801M | -$663M |
| Cash & Equiv.Liquid assets | $369M | $702M |
| Total DebtShort + long-term debt | $1.2B | $39M |
| Interest CoverageEBIT ÷ Interest expense | 3.50x | 65.71x |
DLB leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
VVX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VVX five years ago would be worth $16,724 today (with dividends reinvested), compared to $5,794 for DLB. Over the past 12 months, VVX leads with a +100.7% total return vs DLB's -28.3%. The 3-year compound annual growth rate (CAGR) favors VVX at 25.3% vs DLB's -12.5% — a key indicator of consistent wealth creation.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| YTD ReturnYear-to-date | +63.4% | -16.2% |
| 1-Year ReturnPast 12 months | +100.7% | -28.3% |
| 3-Year ReturnCumulative with dividends | +96.6% | -33.0% |
| 5-Year ReturnCumulative with dividends | +67.2% | -42.1% |
| 10-Year ReturnCumulative with dividends | +251.6% | +32.2% |
| CAGR (3Y)Annualised 3-year return | +25.3% | -12.5% |
VVX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VVX and DLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
DLB is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than VVX's 0.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VVX currently trades 99.1% from its 52-week high vs DLB's 68.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 0.79x |
| 52-Week HighHighest price in past year | $91.64 | $77.00 |
| 52-Week LowLowest price in past year | $43.80 | $51.78 |
| % of 52W HighCurrent price vs 52-week peak | +99.1% | +68.2% |
| RSI (14)Momentum oscillator 0–100 | 81.8 | 33.1 |
| Avg Volume (50D)Average daily shares traded | 471K | 675K |
Evenly matched — VVX and DLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates VVX as "Buy" and DLB as "Buy". Consensus price targets imply 72.0% upside for DLB (target: $90) vs -13.4% for VVX (target: $79). DLB is the only dividend payer here at 2.47% yield — a key consideration for income-focused portfolios.
| Metric | VVXV2X, Inc. | DLBDolby Laboratorie… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $78.60 | $90.33 |
| # AnalystsCovering analysts | 19 | 17 |
| Dividend YieldAnnual dividend ÷ price | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 12 |
| Dividend / ShareAnnual DPS | — | $1.30 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.1% | +3.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
DLB leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). VVX leads in 1 (Total Returns). 1 tied.
Best OverallDolby Laboratories, Inc. (DLB)Leads 3 of 6 categories
Loading custom metrics...
VVX vs DLB: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is VVX or DLB a better buy right now?
For growth investors, Dolby Laboratories, Inc.
(DLB) is the stronger pick with 5. 9% revenue growth year-over-year, versus 3. 7% for V2X, Inc. (VVX). Dolby Laboratories, Inc. (DLB) offers the better valuation at 20. 0x trailing P/E (12. 2x forward), making it the more compelling value choice. Analysts rate V2X, Inc. (VVX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VVX or DLB?
On trailing P/E, Dolby Laboratories, Inc.
(DLB) is the cheapest at 20. 0x versus V2X, Inc. at 37. 1x. On forward P/E, Dolby Laboratories, Inc. is actually cheaper at 12. 2x.
03Which is the better long-term investment — VVX or DLB?
Over the past 5 years, V2X, Inc.
(VVX) delivered a total return of +67. 2%, compared to -42. 1% for Dolby Laboratories, Inc. (DLB). Over 10 years, the gap is even starker: VVX returned +251. 6% versus DLB's +32. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VVX or DLB?
By beta (market sensitivity over 5 years), Dolby Laboratories, Inc.
(DLB) is the lower-risk stock at 0. 79β versus V2X, Inc. 's 0. 85β — meaning VVX is approximately 8% more volatile than DLB relative to the S&P 500. On balance sheet safety, Dolby Laboratories, Inc. (DLB) carries a lower debt/equity ratio of 1% versus 108% for V2X, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VVX or DLB?
By revenue growth (latest reported year), Dolby Laboratories, Inc.
(DLB) is pulling ahead at 5. 9% versus 3. 7% for V2X, Inc. (VVX). On earnings-per-share growth, the picture is similar: V2X, Inc. grew EPS 126. 9% year-over-year, compared to -2. 6% for Dolby Laboratories, Inc.. Over a 3-year CAGR, VVX leads at 15. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VVX or DLB?
Dolby Laboratories, Inc.
(DLB) is the more profitable company, earning 18. 9% net margin versus 1. 7% for V2X, Inc. — meaning it keeps 18. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DLB leads at 19. 6% versus 4. 3% for VVX. At the gross margin level — before operating expenses — DLB leads at 88. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VVX or DLB more undervalued right now?
On forward earnings alone, Dolby Laboratories, Inc.
(DLB) trades at 12. 2x forward P/E versus 14. 9x for V2X, Inc. — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DLB: 72. 0% to $90. 33.
08Which pays a better dividend — VVX or DLB?
In this comparison, DLB (2.
5% yield) pays a dividend. VVX does not pay a meaningful dividend and should not be held primarily for income.
09Is VVX or DLB better for a retirement portfolio?
For long-horizon retirement investors, Dolby Laboratories, Inc.
(DLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79), 2. 5% yield). Both have compounded well over 10 years (DLB: +32. 2%, VVX: +251. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VVX and DLB?
These companies operate in different sectors (VVX (Industrials) and DLB (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
DLB pays a dividend while VVX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.